D-1268-2019 Class II Ongoing

Recalled by Torrent Pharma Inc. — Basking Ridge, NJ

FDA drug recall D-1268-2019 was initiated by Torrent Pharma Inc. on Apr 18, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level. The recall status is ongoing. Affected quantity: 54,084 bottles.

Recall details

Product Type
Drugs
Report Date
May 8, 2019
Initiation Date
Apr 18, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
54,084 bottles

Product description

Losartan Potassium and Hydrochlorothiazide Tablets, USP, 100mg/12.5mg, a) 90-count (NDC: 13668-117-90), b) 1000-count (NDC: 13668-117-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Count, lots, expiry: [90-count bottle] Lot BX35D024, exp 1/31/2020; BEF8D060, BEF8D061, BEF8D062, BEF8D063, BEF8D064, exp 11/30/2020; [1000-count bottle] Lot BEF8D059, exp 11/30/2020; Lots BEF8E004, BEF8E005, exp 1/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1268-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1268-2019. Report a data issue: hello@regdatalab.com.